FDA-approved Product
Therapy Areas
Sanofi focuses on the treatment of adult and pediatric patients 12 years and older with chronic graft versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Educational Resources
Chronic Graft-Versus-Host Disease
GVHD Backgrounder
Overview of chronic graft-versus-host disease
cGVHD Mechanism of Disease (MOD) Interactive Infographic
Interactive Infographic reviewing the pathogenesis of chronic graft-versus-host disease
Organ-Specific Responses with Belumosudil: ASH 2025 Poster
Ad hoc analysis of the ROCKstar data set aimed to evaluate time to response (TTR) and patterns of organ-specific improvement over the first year of belumosudil therapy in participants with long-term follow-up
ROCKreal manuscript (Hall et al., 2025)
Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the US population
schoolROCK Study Overview Card
Review of the schoolROCK study design: Open-label, phase 1/2, multicenter study of belumosudil in children requiring systemic treatment for active moderate to severe cGVHD
Sanofi does not review or control the content of non-Sanofi websites.
Engage with Sanofi Payer Medical
Explore Other Therapy Areas
Immunology and Inflammation Resources
Neurology Resources
Oncology Resources
Rare Blood Disorders Resources
Member Engagement and Population Health Resources
Rare Diseases
Type 1 Diabetes
Established Products
MAT-US-2607372 v1.0 – P. Approved for Distribution. 07/2026